Company intelligence / Profile preview
Barinthus Biotherapeutics
United Kingdombarinthusbio.com ↗
- Ownership
- Public · BRNS
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
Barinthus Biotherapeutics has a focused clinical pipeline built around three proprietary platforms—ChAdOx, MVA, and SNAP. Its lead programs include VTP‑300 for chronic hepatitis B in Phase 2b with positive interim data reported in June 2024; VTP‑1000 for celiac disease in a Phase 1 trial with single ascending dose data expected mid‑2025; and VTP‑850 for recurrent prostate cancer in a Phase 1 trial. The company recently prioritized its pipeline to focus on autoimmune diseases using the SNAP-TI platform.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Viral vector-based immunotherapies (ChAdOx, MVA)Synthetic nanoparticle platforms (SNAP-TI for tolerance immunotherapy, SNAP-CI for cancer immunotherapy)
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
Not specifically detailed in recent sources; historically partnered with University of Oxford on COVID vaccine development as Vaccitech
04
Financials
- Market cap
- $30.2M
- Total revenue
- $0
- Enterprise value
- $-18.8M
Beyond the preview
Go deeper on Barinthus Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Barinthus Biotherapeutics.